Related Experiment Video

Updated: Sep 1, 2025

Author Spotlight: Unraveling Vitamin A Transport Mechanisms — Linking Liver Receptors to Vision Health Through RBPR2 and RBP4 Interactions
08:18

Author Spotlight: Unraveling Vitamin A Transport Mechanisms — Linking Liver Receptors to Vision Health Through RBPR2 and RBP4 Interactions

Published on: October 4, 2024

1.2K

Vitamin D Analogs Bearing C-20 Modifications Stabilize the Agonistic Conformation of Non-Responsive Vitamin D

Anna Y Belorusova1,2,3,4, Daniela Rovito1,2,3,4,5, Yassmine Chebaro1,2,3,4

  • 1Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), F-67400 Illkirch, France.

International Journal of Molecular Sciences
|August 12, 2022
PubMed

Insights

Two novel vitamin D analogs, BXL-62 and Gemini-72, effectively restore the function of mutated Vitamin D Receptors (VDR) linked to rickets, highlighting ligand-receptor adaptation.

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Genetics

Background:

  • The Vitamin D Receptor (VDR) is crucial for calcium balance, cell growth, and differentiation.
  • VDR dysfunction causes diseases like rickets.
  • Developing potent VDR ligands is essential for therapeutic applications.

Purpose of the Study:

  • To evaluate the efficacy of C-20-modified vitamin D analogs (BXL-62 and Gemini-72) in restoring VDR function.
  • To investigate the mechanism of action for these novel VDR ligands.
  • To understand the interaction between VDR variants and novel ligands.

Main Methods:

  • Synthesis and characterization of C-20-modified vitamin D analogs.
  • In vitro assays to assess VDR transcriptional activity.
  • Analysis of VDR variant response to natural and synthetic ligands.
  • Structural analysis of ligand-VDR interactions.

Main Results:

  • BXL-62 and Gemini-72 demonstrated potent VDR agonist activity.
  • These analogs successfully restored transcriptional activity in VDR variants unresponsive to the natural ligand.
  • The study elucidated the mechanism involving mutual adaptation between the ligand and the VDR ligand-binding pocket.

Conclusions:

  • C-20-modified vitamin D analogs show promise in treating VDR-related disorders.
  • These findings provide insights into VDR ligand design and VDR-related disease mechanisms.
  • The study highlights the therapeutic potential of targeting VDR variants.
Keywords:
rare diseasesstructure function relationshipvitamin D

More Related Videos

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.8K
Author Spotlight: Investigating Physiological Functions of Vitamin A Transporters Using HPLC-Based Vitamin A Profiling05:03

Author Spotlight: Investigating Physiological Functions of Vitamin A Transporters Using HPLC-Based Vitamin A Profiling

Published on: December 27, 2024

1.2K

Related Concept Videos

Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.6K
Role of Skin in Vitamin D Synthesis01:23

Role of Skin in Vitamin D Synthesis

The skin plays a crucial role in the synthesis of vitamin D, a vital nutrient for various physiological processes in the body. Vitamin D is unique because it can be synthesized in the skin through a series of chemical reactions triggered by exposure to ultraviolet B (UVB) radiation from sunlight.
The solar UV B rays (290-315 nm) are absorbed by the skin, and 7-dehydrocholesterol (provitamin D3) photolyzes it to previtamin D3, which undergoes a rapid transformation to vitamin...
5.5K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.7K
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
5.6K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
400